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ABSTRACT
Characterization of Chinese Hamster Ovary Cell Performance
with Pentanoic Acid and n-acetyl cysteine Treatment
by
Joseph Camire
Major Professor: Dr. Charles D. Miller
Department: Biological Engineering
Increasing the volumetric titer of recombinant therapeutic proteins is a key
objective in bioprocess manufacturing development. Carboxylic acids have demonstrated
the ability to improve synthesis of recombinant proteins in industrially important cell
lines such as Chinese Hamster Ovary (CHO) cells. The improvement in the production of
recombinant proteins has been linked in a number of molecules to the inhibition of
histone deacetylase, leading to increased transcription of genes. However, carboxylic
acids have been shown to promote an apoptotic response in CHO cell culture. Pentanoic
acid is a carboxylic acid that has demonstrated lower apoptotic response in culture
relative to the carboxylic acid butanoic acid, while maintaining the ability to improve
recombinant protein production.
Supplementation of cultures with anti-oxidants has shown the ability to reduce the
apoptotic response of butanoic acid supplementation leading to increased therapeutic
protein production. Here we show improved production with pentanoic acid and further
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improvements combining induction with supplementation of the antioxidant n-acetyl
cysteine (NAC).
Pentanoic acid induction of CHO cell cultures was studied in time-course
experiments looking at growth, productivity, and apoptosis. Pentanoic acid was shown to
reduce the number of cells entering early apoptosis relative to butanoic acid by 15.4%.
The supplementation of butanoic acid and pentanoic acid treated cultures with n-acetyl
cysteine reduced the population of cells entering early apoptosis by 5.3% and 10.0%,
respectively. A 19.5% increase in productivity was observed in pentanoic acid treated
cultures when supplemented with n-acetyl cysteine. This research provides evidence for a
culture supplementation method that can be used in the optimization of
biopharmaceutical manufacturing processes.
(79 pages)
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PUBLIC ABSTRACT

Characterization of Chinese Hamster Ovary Cell Performance
with Pentanoic Acid and n-acetyl cysteine Treatment
Joseph Camire

To improve the cost of producing protein therapeutics manufacturers can attempt
to increase the amount of protein produced per unit volume. Some small fatty-acids have
shown the ability to increase protein concentrations in some manufacturing systems. An
example system is in the industrially important cell line derived from a Chinese Hamster
Ovary (CHO). A drawback of adding these fatty-acids is they can increase the rate of
cell death.
A potential way to minimize the cell death rate, caused by adding fatty-acids, is to
also add additional anti-oxidants. Through a series of studies, we demonstrate production
with different fatty-acids, butanoic acid and pentanoic acid, with the addition of the
antioxidant, n-Acetyl cysteine (NAC).
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CHAPTER 1
INTRODUCTION

1.1

Background and Significance
Biological pharmaceuticals play a significant role in human health care ranging

from cancer therapy to the breakdown of blood clots during a heart attack. These
biopharmaceuticals drugs are principally produced by recombinant protein technologies,
where gene sequences foreign to a biological host, are used to produce a non-native
protein, in the host cell system. The demand for biopharmaceuticals is large and is
expected to continue to grow over the coming decades. A large number of
biopharmaceuticals rely on mammalian cells as a production vehicle with their ability to
produce bioactive post-translationally modified glycoproteins.
Manufacturing process optimization with a target of increasing the volumetric
production of recombinant proteins can reduce cost and time of the manufacturing
process. A number of carboxylic acids have demonstrated the ability to improve
synthesis of recombinant protein in industrially important cell lines such as Chinese
Hamster Ovary (CHO) cells. The increased productivity attributed to carboxylic acid
has been attributed to the hyper-acylation of histones. Histones are proteins that
deoxyribonucleic acid (DNA) winds around to create chromatin structures in eukaryotic
cell nuclei. The hyperacetylation of the histone unwinds the DNA leaving it more readily
available for transcription, leading to increased gene translation and productivity.
Butanoic acid is a carboxylic acid that has been shown to block cell proliferation in the
G1 cell cycle phase, this may also be a source of increased productivity in some cell lines
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However, butanoic acid supplementation of cultures has been shown to promote
an apoptotic response in CHO cell culture. An alternative carboxylic acid, pentanoic
acid, has been shown to enhance the volumetric productivity of recombinant proteins
(Liu et al. 2001).
Supplementation of cultures of cells with anti-oxidants has shown the ability to
reduce the apoptotic response to carboxylic acid supplementation leading to increased
therapeutic protein production. Antioxidant addition to cultures can improve posttreatment performance of cultures by minimizing apoptosis.
With an optimization target of increasing recombinant protein production in CHO
cell lines a screen of multiple carboxylic acids was performed. Selected carboxylic acids
were then screened with an antioxidant for further improvement of recombinant protein
production.
Here we show improved production with pentanoic acid and further
improvements combining induction with supplementation of the antioxidant n-acetyl
cysteine (NAC).
1.2

Hypothesis
Small molecules can enhance the level of heterologous recombinant protein

production. However, it has been observed that treatment with small molecule enhancers
can induce apoptosis in the cultures. Antioxidants addition to these cultures can improve
post-treatment performance of cultures by minimizing apoptosis.
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1.3

Research Objectives
As a screening tool, analyze the performance of components as single parameters

to observe does response concentration curves. Using a scale-down model 96 well
microtiter plate culture system, gradients of test components will be analyzed over initial
ranges of 0-20mM. The objective is to determine response concentrations of test
components.
Design and analyze experiments looking at primary and secondary effects of
combinations of selected small molecules and antioxidants. Assuming that Small
Molecule Enhancers improve volumetric productivity, but have a negative impact on
growth kinetics and that antioxidants show neutral to improved productivity or growth
kinetics a factorial design of experiment is proposed to explore the possibility of
improved performance from antioxidant addition to Small Molecule Enhancer induced
cultures.
Explore the cause of reduced culture performance following induction with Small
Molecule Enhancers and any positive effects from treatment with antioxidants.
Apoptosis stimulation will be explored as an explanation for reduced culture growth
performance after addition of Small Molecule Enhancers. Assuming apoptosis explains
reduced culture performance, the effect of addition of anti-oxidants on apoptosis will be
explored.
1.4

References

Liu CH, Chu IM, Hwang SM. 2001. Pentanoic acid, a novel protein synthesis stimulant
for Chinese hamster ovary (CHO) cells. Journal of Bioscience and Bioengineering
91(1):71-75.
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CHAPTER 2
LITERATURE REVIEW

2.1

Biopharmaceuticals
Over the last 35 years biopharmaceuticals have played an increasingly important

role in human and animal health. As opposed to traditional chemical pharmaceuticals,
typified by small molecule drugs, biopharmaceuticals are biotechnology-derived.
Biopharmaceuticals encompass a broad range of treatments for areas that include
arthritis, enzyme replacement, allergy, cancer therapy, infertility, cardiology,
inflammatory diseases, blood disease, myocardial infarction, cystic fibrosis, organ
transplant, and tissue growth and repair. Within the broad category of
biopharmaceuticals are a variety of compounds and treatments; nucleic acids including
gene therapies, vaccines, cell therapy, and therapeutic proteins. Within therapeutic
proteins are three main categories; recombinant proteins, monoclonal antibodies, and
purified proteins. An example of a recombinant protein is Octocog (Table 1), a blood
enzyme known as Factor VIII. It is used as an enzyme replacement therapy in the
treatment of hemophilia A. An example of a monoclonal antibodies is Adalimumab
(Table 1) a recombinant human IgG1 that targets human tumor necrosis factor-alpha
(TNF-alpha). It is a glycosylated protein that contains 1,330 amino acids and has a
molecular weight of about 148 kilodaltons (Vena and Cassano 2007). Adalimumab is
able to bind TNF-alpha, a naturally occurring cytokine involved in inflammatory and
immune response (Arora 2007), thus blocking its ability to bind to the TNF-alpha cell
surface receptors, p55 and p75.
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Table 1 Select list of FDA approved biopharmaceuticals that have reached
blockbuster status (>$1 billion) in sales.(Bioplan Associates 2013)
Name
Adalimumab
Bevacizumab
Epoetin alfa
Etanercept
Infliximab
Insulin Glargine
Octocog
Pegfilgrastim
Ranibizumab
Rituximab
Trastuzumab

Product
TNF MAb
VEGF MAb
EPO
TNF receptor-IgG
Fc
TNF MAb
Insulin Glargine
Factor VIII
G-CSF Pegylated
VEGF MAb Fab
CD20 MAb
HER2 Receptor
MAb

Class
Monoclonal Antibody
Monoclonal Antibody
Recombinant Protein
Monoclonal Antibody
Fragment
Monoclonal Antibody
Recombinant Protein
Recombinant Protein
Recombinant Protein
Monoclonal Antibody
Fragment
Monoclonal Antibody
Monoclonal Antibody

Cell Line
CHO
CHO
CHO
CHO
SP2/0
Escherichia coli
CHO
Escherichia coli
Escherichia coli
CHO
CHO

In 2013 it was estimated that there were 435 biopharmaceuticals approved for use
in the United States and Europe (Bioplan Associates 2013). Of the approximately 10,000
therapeutic in R&D, it is estimated that 40% are biopharmaceuticals. In 2013 it was
estimated that biopharmaceuticals had a market size of about $165 billion and was
growing at a 15% compounding annual growth rate. This market size represents
approximately 15% of the estimated $1 trillion total pharmaceutical market. It is
estimated that the biopharmaceutical market will grow to greater than $210 billion by
2015 (Technavio 2013). The biopharmaceutical industry group, PhRMA, estimated that
in 2012 there was $48.5 billion spent on research and product development innovations
(PhRMA 2013). It is projected that this funding trend will continue with the potential
for nearly 50% of pharmaceutical R&D projected to be devoted to biopharmaceuticals
(Bioplan Associates 2013).
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2.2

Monoclonal Antibodies
Within biopharmaceuticals, monoclonal antibodies are an important segment.

Seven of the top ten selling biopharmaceuticals in 2011 were monoclonal antibodies or
fragments of monoclonal antibodies. Monoclonal antibodies are natural occurring
glycosylated proteins that play a major role in the body’s immune system. They are
monospecific to an antigen and are produced by B lymphocytes, a class of immune cells,
in response to an antigen. Specific B lymphocyte only produces one specific antibody
and have limited, to no proliferation capacity. In 1975, George Kohler and Cesar
Milstein demonstrated that a specific B cell could be isolated and fused with a cancerous
myeloma cell line. The B cell bringing the ability to produce a specific antibody and the
myeloma cell conferring the ability to replicate rapidly and indefinitely. This process,
known as hybridoma technology, ushered in a process to allow expanded production of a
monoclonal antibody to a specific target molecule. One method for producing the B cell
needed for the fusion is to expose a mouse to an antigen in two phases, a priming dose
and a booster dose. Following treatment with the antigen a sample of the spleen can be
harvested. Following fusion with the myeloma cell line the hybridoma population can be
screened for a population producing the antibody of interest.
Immune recognition and response in humans to IgG produced in other species
prompted the move to more human-like IgG. Most therapeutics antibodies are either
humanized or are fully human IgG and are produced as recombinant glycoproteins in
mammalian cells (Beck et al. 2008). Humanized monoclonal antibodies are genetic
constructs that contain both human and non-human gene sequences for specific antibody
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regions, the conserved genetic regions coming from human sequences and the variable
genetic sequences, specific to an antigen, regions coming from species donating the Bcell Lymphocyte.
MAb are generally expensive therapies that can cost more than $100,000 per year
or over the course of full treatment (Bioplan Associates 2013). The high cost of MAb
treatment can be attributed to low potency and short half-life, requiring large and frequent
dosages. These factors lead to large amounts of MAb being needed to treat patient
populations. It is estimated that around 90% of the world-wide production capacity for
mammalian cell culture is for MAb production (Bioplan Associates 2013). Much of this
production requires the use of large volume bioreactors at the 10,000 L scale.
2.3

Recombinant DNA Technology
With the introduction of recombinant protein production in 1974 by Herbert

Boyer at University of California San Francisco and Stanley Cohen at Stanford it was
possible to engineer systems for the manufacturing of biopharmaceuticals, rather than
purification of proteins from source tissue and organs. Recombinant proteins and
glycoproteins are the products of exogenous gene sequences. These recombinant genes
can be spliced into the genome of alternative cells to be used as a production system.
The alternative cell line systems provide the gene replication, transcription, translation,
and if required the secretion of the targeted proteins and glycoproteins. Recombinant
gene expression cassettes typically contain promoters, initiation sequences and may
contain introns and exons, and coding sequences such as polyadenylation signals.
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The predominant production system for biopharmaceuticals use recombinant
DNA technology. Early recombinant engineered systems relied on proteins produced in
bacterial systems. E. coli are an example of a bacterial production system used to
produce recombinant proteins that lack typical mammalian post-translational
modifications. When complex, human-like post-translational modifications are needed
then mammalian cells are the typical system used for biopharmaceutical production. The
primary post-translational modification is protein glycosylation, a modification where
polymers of sugars are attached to proteins.
These drugs have played an important role in human health care over the last 30
years (Brown 2005; Carter 2011). A typical development process for production using
recombinant DNA would start with identification of a target gene sequence (Figure 1).
An expression cassette may be developed then used in a transient expression system.
Transient expression systems rely on introduction of the recombinant DNA into the cell
line, but the gene isn’t incorporated in the cell genome. However, using the native
cellular processes the gene of interested is transcribed and then the target proteins in
translated from the transcribed mRNA. The resulting recombinant protein can then be
tested for bioactivity and toxicity. Transient production systems are typically low-level
production systems, thus requiring the production of stable cell line for optimized protein
expression. Selected genes are then used to produce stable cell lines that have the gene
incorporated into the production cell line genome.
Within biopharmaceutical production, Chinese Hamster Ovary cells are one of the
predominate cell systems used, because of relatively straightforward genetic
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manipulation of the cell line, growth of the cell line is rapid and can be optimized, and
general acceptance of use of this cell line by government regulatory bodies such as the
FDA and EMEA.

Figure 1 Flow diagram of development of a recombinant production cell line.

Recombinant cell lines used for production are generally screened in a clonal
selection process, to eliminate non-producers and select clones with higher production
rates. Chosen clones can then be optimized in scale-down model systems of full largescale production processes.
2.4

Production of Biopharmaceuticals.
The production of human therapeutics that require unique processing to be active,

relies on mammalian cells because of their ability to correctly fold, perform posttranslational modifications, and secrete proteins that aren’t possible in microbial and
plant-based systems. (Omasa et al. 2010a)
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Mammalian cell culture can be traced back to organ culturing techniques in the
19th century. By the 1950’s many procedures had been developed for culturing cells
outside of mammalian cells. Of main importance in advancing the process, at this time,
were studies in the production of virus. To facilitate growth in vitro culture conditions
were created similar to the environment in vivo, with serum being a primary constituent
in most culturing systems. Serum being an animal-blood product provided many
important factors, including, metabolites, growth factors, mitogens, lipids, and proteins.
To minimize the use of serum, a costly and variable component, basal liquid formulations
consisting of carbohydrates, to supply energy, amino acids, vitamins and salts were
developed. Although an undefined supplement, serum played an important role in
culturing, supplying growth factors, lipid carriers, antioxidants, protease inhibitors,
however, its undefined character could lead to variability in performance. Its collection
from abattoirs as a byproduct of the beef industry made it subject to variability in supply
with the result that as a commodity it price could fluctuate dramatically. The
development of basal media formulations allowed for serum to be reduced to levels of 515% of culture volume and in some cases to be eliminated altogether. When
biopharmaceutical production started to develop and grow in the 1970’s and 1980’s,
serum was still an important culture supplement for production. By the 1990’s
formulations and culturing methods were beginning to be introduced for protein
production without the use of serum. Because of product life cycles, cost to develop new
processes and systems, there are many legacy products that are still manufactured using
serum.
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Along with advancements in culture media formulations, systems for
manufacturing have advanced over the last three decades. Processes for
biopharmaceutical production include batch, fed-batch, and perfusion or variations of
these systems. Some manufacturing processes rely on batch methods for their simplicity,
although most processes are currently fed-batch processes. This manufacturing method
lends itself well to serum-free formulation advancements in the last two decades, since
known depleted components could be fed into the process during culture processes.
Although perfusion-based systems of production have been developed, views that they
are complex have limited their use. However, current pushes in development are
focusing on perfusion as ideal manufacturing system of future production platforms.
After identification of the product of interest and production cell line generation,
the next step is production of a Master Cell Bank. A production process (Figure 2) would
then start with a Working Cell Bank being produced. Typically, cell banks consist of
small volume aliquots of cells preserved in cryostorage, in volumes in the 0.5 to 10mL
range.

Figure 2 Bioprocess Schematic showing seed train procession.
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Production of biopharmaceuticals in mammalian cell lines remains an expensive
and complex process. Increasing the volumetric titer of recombinant therapeutic proteins
is a key objective in bioprocess manufacturing development. To achieve higher product
titers, driving down cost, researchers have employed multiple strategies. A typical
process will use suspension cells (Figure 2), were cells grow detached from contact
surfaces. Processes over the last 20 years have increasingly been engineered to use
serum-free cultures to minimize cost in the production bioprocess and in purification of
target proteins in downstream processes.

Figure 3 Photomicrograph of suspension CHO Cells settled on to tissue culture
flask bottom.

Modifications in the culture conditions and genetic based engineering of cell lines
used for production of recombinant targets have played a significant role in optimization
of production. A frequent optimization target is arresting the cells in G1 cell cycle phase,
due to reduced cell growth and higher protein production. Three methods capable of the
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growth arrest are: temperature shift, cell engineering, and bioactive chemicals.
Temperature shifting resulting in cell cycle arrest can improve transcription, translation,
cytoskeletal rearrangement, with reduced metabolic activity. The reduced metabolism in
the cells is reflected in reduction in glucose metabolism and oxygen consumption (Kumar
et al. 2007; Meleady 2007). Cell engineering approaches can target the integration of
genes for over expression such as Bcl-2, a regulatory protein involved in apoptosis
mediated cell death (Tey et al. 2000).

Figure 4 Schematic of typical batch/fed-batch profile of culture kinetics.
Production of target protein frequently shows peak accumulation in plateau and the
decline phase of culture.

2.5

Post Translational Modifications
It has been found that many protein based biologics require post translational

processing for biological activity (Butler 2005). Glycans on the surface of proteins play
an important role in immune function. They are generally specific to a species and non-
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native glycan structures can trigger immune response and high clearance rates of foreign
proteins from the body. Improperly glycosylated proteins can trigger immunogenic and
allergic response and accelerate clearance of the protein from the body. Glycosylation
can be affected by the choice of manufacturing process and clonal variation.

Golgi

Endoplasmic
Reticulum
Nucleus

Figure 5 Mammalian Cell rProtein processing
(Note: Similar to NEB diagram (Omasa et al. 2010b) )

2.6

Small Molecule Enhancers
Bioactive molecules can target many cellular mechanisms ranging from metabolic

to genetic changes. Important to bioprocessing are molecules that can stimulate the
improved production of recombinant proteins. A wide variety of molecules have been
studied for this purpose, for example quinoline thioethers (Kazi et al. 2010), dimethyl
sulfoxide (Fiore et al. 2002; Li et al. 2006; Liu and Chen 2007; Liu et al. 2001b; Wang et
al. 2007), and aurintricarboxylic acid (Liu et al. 2001a). Additionally, broad classes of
small molecule in the categories of aromatic carboxylic acids, hydroxamic acids, and
acetamides have been studies (Allen et al. 2008).
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Short chain fatty acid (SCFA), a class of saturated monocarboxylic acids, have
been shown to have many biological functions, including regulating gene transcription
(Meng et al. 1999) and inhibition of histone deacetylase (Augenlicht et al. 2002). There
are a number of SCFA that are important in cells, varying in their carbon backbone
length; acetate (C2), propionate (C3), butanoate (C4), pentanoate (C5), and caproate
(C6). The most widely studied of these, for increased protein production in
bioprocessing, has been butanoic acid (C4) and has demonstrated a wide effect on cells.
Butanoic acid has been implicated in cell proliferation, gene transcription regulation,
differentiation, and apoptosis (Augenlicht et al. 2002; Kim and Lee 2002; Sung et al.
2004). Butanoic acid has been shown to stimulate the gene coding for metallothionein.
Metallothionein (MT) are small cysteine-rich metal binding proteins. MT plays an
important role in maintaining zinc and copper homeostasis in cells and can detoxify
harmful metals such as cadmium (Liu et al. 1992).

Table 2 Select table of SCFA and the antioxidant n-Acetyl Cysteine (Chemical
Structure Source PubChem Compound http://pubchem.ncbi.nlm.nih.gov/)

1

IUPAC
Name:

Common
Name

CID1#

MW

Molecular
Formula

Butanoic acid

Butanoic
Acid

264

88.11

C4H8O2

http://pubchem.ncbi.nlm.nih.gov/citations.html

2D Structure
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Pentanoic acid

Valeric Acid

7991

102.13

C5H10O2

Butanoic acid was demonstrated to increase protein production by Gorman et al
(Gorman et al. 1983). An increase in the enhancer-dependent transcription of an SV40
promoter was approximately 30-fold higher in Hela Cells. The increased production of
chloramphenicol acetyltransferase (CAT) in these cells was attributed to the
hyperacetylation of histones, thus opening the chromatin structure in critical regions
spanning the enhancer and the adjacent promoter, leading to increased transcriptional
efficiency.
The inhibition of histone deacetylase is one of the most widely studied effects of
butanoic acid treatment. Inhibition of histone deacetylase leads to hyper-acetylation of
histone molecules, a class of DNA packaging molecules, which opens gene regions
making them more readily available for transcription, leading to increased mRNA levels,
with increasing translation and productivity. However, butanoic acid has a welldocumented effect of inducing apoptosis in cells it is used to treat.
Additionally, Butanoic acid has been shown to block cell proliferation in the G1
cell cycle phase, this may also be a source of increased productivity in some cell lines. A
limitation to the use of carboxylic acids is increased levels of apoptosis observed in
treated cultures.
The effect of butanoic acid induction of the production of recombinant human
thrombopoietin (hTPO) produced in Chinese Hamster Ovary cells has been studied for its
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impact on the heterogeneity and biological activity of the protein (Sung et al. 2004). The
human thrombopoietin protein is a highly glycosylated protein with six N-glycosylation
sites and 24 O-glycosylation sites. The post-translational glycosylation of recombinant
proteins has been shown to be effected by the treatment of cultures of CHO cells with
sodium butyrate (Chung et al. 2001; Santell et al. 1999). Sung et al. were able to achieve
a peak hTPO concentration of 82.2 ± 5.6 ug/mL treating cells growing in exponential
phase with 3 mM butanoic acid. This group demonstrated that compared to a control
culture, a 6.4-fold increase in specific productivity, q TPO, and a 3.3-fold increase in
volumetric productivity on day 7 of the culture. The butanoic treated culture
demonstrated diminished protein quality in the form of a lower level of acidic forms of
hTPO being produced. Additionally, they demonstrated lower biological activity of the
butanoic acid treated hTPO.
Oster et al. demonstrated improved productivity for the recombinant production
of the plasma extracellular membrane-anchored enzyme, -glutamyl transferase (GGT,
EC2.3.2.2) by sodium butanoate (Oster et al. 1993). Using a cytomegalovirus immediate
early promoter in a CHO cell line, they demonstrate a 3 to 5-fold increase in production
of GGT. They observed increase levels of rGGT mRNA production following butanoic
acid induction. The resulting rGGT was characterized and demonstrated to be equivalent
to non-induced control culture rGGT.
The use of short-chain carboxylic acids such as pentanoic acid (Liu et al. 2001c)
has been shown to enhance the volumetric productivity of recombinant proteins produced
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in bioprocesses. The addition of antioxidants in cultures treated with the carboxylic acid,
butanoic acid, has lowered the levels of apoptosis observed (Oh et al. 2005).
Carboxylic acids have demonstrated the ability to improve synthesis of
recombinant protein in industrially important cell lines such as Chinese Hamster Ovary
(CHO) cells. However, some carboxylic acids have been shown to promote an apoptotic
response in CHO cell culture. Chi-Hsien Liu, et al(Liu et al. 2001c), researched the small
molecule enhancement of protein production by a group of nine carboxylic acids by
themselves and in combination. They found that the five-carbon carboxylic acid,
pentanoic acid, showed higher relative protein titer increase compared to the well publish
butanoic acid counterpart. They also demonstrated results for lower apoptotic cell effect.
A number of carboxylic acids, formate, acetate and 2-methyl butyrate showed slight
enhancement effects on cell growth and production. Some carboxylic acids, such as Lalpha-amino-n-butanoic acid showed slight enhancements in growth but no enhancement
of production. It was demonstrated that when the carbon backbone range was between 3
to 5 carbons, there was a marked increase in titer enhancement. Slightly higher growth
and a better protein production enhancement were observed for the 5 carbon pentanoic
acid over the 4 carbon butanoic acid. To try and explain these results the authors looked
at apoptosis as an explanation for the results. Butanoic acid is a well-known enhancer of
protein production (Lamotte et al. 1999; Mimura et al. 2001), but also has a welldocumented apoptotic affect (Kim et al. 2003). In these studies, it was found that
butanoic acid had about double the apoptotic affect that pentanoic acid had using an
arbitrary apoptosis ratio. The method used was a cell death detection ELISA kit looking
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at DNA fragmentation. Of note in these studies is the relative low producer used in the
studies. Whereas a common fusion antibody produces from 500mg to 5 g per liter, the
cell line used by Liu only produced a maximum of 620 ug per liter, or about 1:800 of a
common producer cell line.(Preithner et al. 2006)
It is important that a good process strategy be used to maximize productivity of
culture(Franco-Lara and Weuster-Botz 2005). A number of newer small molecule
enhancers have been developed that are based on aromatic hydrocarbons. These haven’t
been compared to pentanoic acid (Allen et al. 2008).
2.7

Apoptosis
Apoptosis is programmed cell death triggering a biochemical cascade of events

leading to cell destruction. The cascade of the events includes cell blebbing,
fragmentation of the DNA and the nucleus.

Figure 6 Diagram of apoptosis process in cells with illustration of Annexin V and
Propidium Iodide analysis of cell state.
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2.8

Antioxidants
Oxidative stress is a major factor limiting production and quality of product

produced in recombinant systems. Many antioxidants have been studied for their
protective and enhancing effect on cells. Antioxidants demonstrate the ability to reduce
stress in the endoplasmic reticulum, a key site of glycosylation (Malhotra et al. 2008).
2.8.1

Use of Antioxidants in combination with Small Molecule Enhancers
Antioxidants have been used extensively in cell culture. An example is the work

done by Oh et al. (Oh et al. 2005). This group evaluated a panel of eleven antioxidants
using a Plackett-Burman statistical design. In their work they demonstrated that of the
panel tested only n-Acetyl cysteine (NAC), seen in Table 3, showed increased longevity
of cell culture and increased production of the target protein, recombinant interferon-β1A (IFN-β). In butanoic acid treated cells, NAC treatment was able to extend culture
longevity greater than 8 days and increased recombinant INF-β production 2-fold when
compared to control cultures that were treated only with butanoic acid. They further
demonstrated that the glycosylation patterns of the INF-β, studied using isoelectric
focusing (IEF), showed increased levels of lower pI isoforms compared to the control
run. The recombinant INF-β from NAC treated cultures had a 17.7% higher level of
sialic acid content when analyzed by HPLC.
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Table 3 Chemical Description of n-Acetyl cysteine.
Common
Name
n-Acetyl
Cysteine

2.9

IUPAC Name:

CID2#

MW

Molecular
Formula

(2R)-2acetamido-3sulfanylpropanoic
acid

12035

163.19

C5H9NO3S

2D Structure

Chinese Hamster Ovary Cell Line
Production of biopharmaceuticals has come to rely on mammalian cells; in

particularly they have come to rely on Chinese Hamster Ovary cells. The predominant
cell line used in the production of biopharmaceuticals is the Chinese Hamster Ovary
(CHO) cell line (Jayapal et al. 2007). This cell line was derived from a female Cricetulus
griseus hamster in 1957, by Dr Theodore Puck in the Department of Medicine at the
University of Colorado. Cricetulus griseus have a low chromosome number (2n=22).
The key cell line used in biopharmaceutical production, derived from C. griseus, CHOK1, has been shown to be heteroploidy. It was observed early on that the cell line was
relatively easy to cultivate in vitro and had a good growth rate, with specific growth rates
that can range from 0.04 - 0.06 hr-1.
Important to the development of CHO cells for biopharmaceutical production
were observations of the CHO genome being relatively easily manipulated and the
development of expression and amplification systems. The dihydrofolate reductase
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(DHFR) selection and amplification system and the glutamine synthetase (GS) selection
and amplification system (Camire 2000). The DHFR expression system relies on the
critical path for DHFR in the production of nucleotides for DNA (Figure 7) synthesis and
replication.

Figure 7 Schematic of DHFR enzyme process.

Important to the development of this expression system was the development of
DHFR knockout cell lines in Dr. Larry Chasin’s lab at Columbia University. The CHO
DUKX B11 and the CHO DG44 cell lines are single and double allele knockouts of the
DHFR gene, respectively, and were generated by the use of mutagens. In the absence of
nucleic acids and the precursors hypoxanthine and thymidine, these cell lines cannot
replicate and unsupplemented populations die off. Incorporating the DHFR gene into an
expression cassette with a gene of interest allows the recombinant cell line to live in a
selection medium without nucleic acid precursors and hypoxanthine and thymidine.
Another important feature of this system is the dose response competitive inhibition of
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the DHFR enzyme by the compound methotrexate (CAS Number 133073-73-1). By
increasing the concentration of methotrexate in a culture of CHO cells with an expression
cassette containing DHFR, successive populations of cells that have increasing copies of
DHFR and the corresponding gene of interest are selected for. In this way gene copy
number amplified populations can be selected that can have two to thousands of desired
genes (Kaufman et al. 1985).
The GS expression system relies on the conversion of glutamate and ammonium
to the amino acid glutamine (Figure 8). This system has been shown to be effective in
both knockout and wild-type cell lines containing a native GS gene. Similar to DHFR
expression systems the glutamine synthesis enzyme can be competitively inhibited by
methionine sulfoximine (CAS Number 15985-39-4).

Figure
8 Schematic of GS selection system.
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Chapter
SCREENING OF SHORT CHAIN FATTY ACIDS AND AN ANTIOXIDANT WITH
CHINESE HAMSTER OVARY CELLS

3.1

Introduction
Tissue plasminogen activator (tPA) is a 68 kDa monomeric serine protease (EC

3.4.21.68) produced primarily by endothelial cells. In blood, it is one of two major activators of
plasminogen, the precursor of plasmin which is a serine protease that can dissolve fibrin blood
clots. A recombinant form of the protein is produced as a biopharmaceutical drug, Activase®,
for treatment of acute myocardial infarction, acute ischemic stroke, pulmonary thrombosis, and
other blood clot conditions (Wagstaff et al. 1995). Its production is done in CHO cells and acts
as a model for non-IgG biopharmaceutical recombinant protein production systems.
Bioactive chemicals can target many cellular mechanisms including protein expression.
One of the targeted mechanisms is to induce cell stress to cause up regulation of protein
production. A wide variety of molecules have been used to promote increased protein
production in recombinant cell lines, for example quinoline thioethers (Kazi et al. 2010),
dimethyl sulfoxide (Fiore et al. 2002; Li et al. 2006; Liu and Chen 2007; Liu et al. 2001b; Wang
et al. 2007), and aurintricarboxylic acid (Liu et al. 2001a). Additionally, broad classes of small
molecule in the categories of aromatic carboxylic acids, hydroxamic acids, and acetamides have
been studies (Allen et al. 2008).
One of the most studied molecules for stimulation of protein production is butanoic acid.
Butanoic acid is a short chain fatty acid (SCFA), a class of saturated monocarboxylic acids.
SCFA have been shown to have many biological functions, including regulating gene
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transcription (Meng et al. 1999) and inhibition of histone deacetylase (Augenlicht et al. 2002).
There are a number of SCFA that are important in cells; acetate (C2), propionate (C3), butanoate
(C4), pentanoate (C5), and caproate (C6). The most widely studied of these has been butanoic
acid (C4) and has demonstrated a wide effect on cells (Table 3). Butanoic acid has been
implicated in cell proliferation, gene transcription regulation, differentiation, and apoptosis
(Augenlicht et al. 2002; Kim and Lee 2002; Sung et al. 2004). Butanoic acid has been shown to
stimulate the gene coding for metallothionein. Metallothionein (MT) are small cysteine-rich
metal binding proteins. MT plays an important role in maintaining zinc and copper homeostasis
in cells and can detoxify harmful metals such as cadmium (Liu et al. 1992).
Butanoic acid was demonstrated to increase protein production of by Gorman et al
(Gorman et al. 1983). An increase in the enhancer-dependent transcription of an SV40 promoter
was approximately 30-fold higher in Hela Cells. The expression increases of chloramphenicol
acetyltransferase (CAT) in these cells was attributed to the hyperacetylation of histones, thus
opening the chromatin structure in critical regions spanning the enhancer and the adjacent
promoter, leading to increased transcriptional efficiency.
The inhibition of histone deacetylase is one of the most widely studied effects of butanoic
acid treatment. Inhibition of histone deacetylase leads to hyper-acetylation of histone molecules,
a class of DNA packaging molecules, which opens gene regions making them more readily
available for transcription, leading to increased mRNA levels increasing translation and
productivity. However, butanoic acid has a well-documented effect of inducing apoptosis in
cells it is used to treat.
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Table 4 Small Molecules used in this screening study.

3

Compound/
Stock
Concentration

CAS Number

MW

Abbreviation

Pentanoic Acid
500 mM

109-52-4

102.1

PA

Butanoic Acid
250 mM

107-92-6

88.11

BA

N-Acetyl Cysteine
250 mM

616-91-1

163.19

NAC

Hydrocinnamic
250 mM

501-52-0

150.17

HCA

4-Phenylbutanoic
Acid
250 mM

217-341-8

164.20

4PBA
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3.2
3.2.1

Materials and Methods
Cell Line and Media
A Chinese Hamster Ovary cell line, CHO 1-15 500 (ATCC® CRL-9606), producing

human tissue Plasminogen Activator (tPA) was used for these studies. The cell line had
previously undergone dihydrofolate selection and amplification with 50 nM methotrexate. The
cell line was cultured using the chemically-defined serum-free medium CDM4CHO® (HyClone,
Thermo Fisher Scientific, Waltham, Massachusetts) with 4mM L-Glutamine. Cell stocks were
maintained in 100 mL cultures in 250 mL shake flask in a 37°C, 5%CO 2 incubator, passaged
every 3 to 4 days.
3.2.2

Component Preparation
All compound tested were prepared in deionized process water and were sterile filtered

using 0.2 um sterilizing grade bottle top filters. Butanoic Acid, n-Acetyl –cysteine,
hydrocinnamic acid, 4-Phenylbutanoic acid were prepared at a concentration of 250mM and
Pentanoic acid was prepared at a concentration of 500mM.
3.2.3

Bioprocess Experiments
Disposable 125mL Erlenmeyer shake flasks were used for scale-down culture analysis of

the short chain fatty acids and n-acetyl cysteine. Experimental conditions were cultured using a
base formulation of CDM4CHO® (HyClone, Thermo Fisher Scientific, Waltham,
Massachusetts) in a fed batch process using a custom formulation process supplement PS320
(HyClone, Thermo Fisher Scientific, Waltham, Massachusetts). The PS320 process supplement
contains carbohydrates, amino acids, and vitamins. This formulation, PS320:60 8.0, was prepared
at a concentration of 60g/L by using adjustments to pH 9.0 with 1N NaOH followed by
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adjustment with 1.0 HCl to pH 8.0 followed by the addition of 3.2 g/L sodium bicarbonate. The
formulation was then sterile filtered using a 0.2 um sterilizing grade bottle top filter.
A single 2.8 L disposable Fernbach flask was seeded at an initial volume of 600 mL
(0.8Vf) at a cell density of 250,000 cells/mL on day 0. The culture was fed two times with 75
mL (0.1Vf) PS320:608.0 on day 3 and on day 5. Following the feeding of the culture on day 5,
cells were distributed into independent culture flasks in preparation for treatment with designated
culture test conditions. Cultures were sampled on days 0, 3, 5, 7, and 10 for cell quantitation,
viability analysis and product titer.
3.2.4

Cell Quantitation
Cell density and viability were determined using Trypan Blue dye exclusion assays.

Microtiter plate cultures were counted using on a Cellavista® Cell Imager (SynenTec, Elmshorn,
Germany). Shaker flask cultures were counted using an automated ViCell® XR Cell Viability
Analyzer (Beckman Coulter, Fullerton, California). Aliquots for cell counting were counted
immediately after sampling.
3.2.5

Product Titer Analysis by Enzyme-Linked Immunosorbent Assay
Product titer was determined using a sandwich enzyme-linked immunosorbent assay

(ELISA). An affinity purified sheep anti-tPA IgG was used as a capture antibody by coating a
standard ELISA 96 well plate. A reference standard curve was generated using a concentrated
and titered recombinant tPA control in the range of 3.16 to 1000 ug/mL. Samples from culture
conditions which had previously been stored frozen at -20°C were thawed and dilutions were
prepared in phosphate buffered saline (PBS) at a dilution factor of 1:2000. Samples were then
applied to the capture antibody prepared ELISA plates. A sheep anti-tPA conjugated to horse-
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radish peroxidase was used as the detecting antibody. A stable liquid one-step 3,3′,5,5′tetramethylbenzidine (TMB) liquid was used as a substrate for colorimetric analysis. A
SpectraMax M2 (Molecular Devices, Sunnyvale, CA) was used to analyze the assay plates at a
detection wavelength of 450 nm.
𝐼𝑉𝐶𝐷 =

𝐼𝑉𝐶𝐷 =
𝒊

3.3

𝒚𝒊 + 𝒚𝒊
𝟐

𝑥 𝑑𝑡
𝟏

∗ (𝒙𝒊 − 𝒙𝒊 𝟏 )

Results and Discussion
To determine the effect of multiple small molecules and an antioxidant for their potential

to enhance volumetric protein production, a CHO cell line producing tPA was subjected to
gradients of the components (Figure 9).
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Figure
9 Growth promotion analysis of carboxylic acid treatment conditions.

The fed batch control condition showed a large decline following day 7. A significant
improvement was observed in the cell growth for samples treated with n-Acetyl-Cysteine. The
n-Acetyl-Cysteine cell conditions didn’t suffer the precipitous decline in cell density and
viability observed with the fed-batch control. This may be attributed to a large decline in
viability at this point (Figure 10).
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Figure
10 Plot of viability for carboxylic acid treatment conditions.

Higher concentration treatments at the 5 mM level of Sodium Butyrate, Pentanoic acid,
Hydrocinnamic acid, and 4-Phenylbutyric acid showed almost complete inhibition of cell growth
starting at time of treatment (Figure 11).
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Figure
11 Growth promotion of 5mM concentrations components causing reduced performance.

The largest volumetric productivity increase was observed in the 5mM Sodium Butyrate
treatment condition, 72.01 mg/L (Table 1). However, Pentanoic acid showed a loss of
volumetric productivity at 2.5 mM and 5.0 mM treatment levels. The peak volumetric
productivity at 1.25 mM Pentanoic acid was 50.93 mg/L which was only 70.7% of the peak
volumetric productivity of Sodium Butyrate at 5mM.
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Table 5 Result of gradient testing of select SME and the antioxidant NAC.
ICA (celldays/mL)
Fed batch Control
NAC 2.5 mM
NaBu 5 mM
PA 1.25 mM
HCA 0.625 mM
4PBA 0.625 mM

Control
NAC
NB
PA
HCA
4PBA

SME Conc
(mM)
0.000
2.500
5.000
1.250
0.625
0.625

Integral Cell Area
34.05
45.25
22.04
34.56
36.70
26.80

tPA (mg/L)
Volumetric
Productivity
48.03
62.19
72.01
50.93
43.14
24.74

X' (pg/cell/day)
Specific Productivity
1.41
1.37
3.27
1.47
1.18
0.92

Considering the integral cell area of treatment conditions, n-Acetyl-Cysteine showed
decline in culture performance at the 10mM level compared to the 5mM level, 31.21 celldays/mL compared to 45.83 cell-days/mL, respectively, a 31.9% drop. Peak volumetric
productivity for n-Acetyl-cysteine, 62.19 mg/L was observed at 2.5 mM which was 64.2%
higher than that observed at the peak cell performance level at the 5mM concentration.
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Figure 12 Plots of Integral Cel lArea , Viability, and Specific Productivity for n-Acetyl
Cysteine (NAC), Sodium Butyrate (NB), and Pentanoic Acid (PA) condictions.
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Figure 13 Plots of Integral CellArea , Viability, and Specific Productivity for Sodium
Butyrate (NB), Hydrocinnamic Acid (HCA), and 4-Phenylbutanoic Acid (4PBA).

3.4

Conclusion
Multiple small molecules were demonstrated to show gradient dependent response to cell

growth and protein production. In this tPA producing cell line the best protein production was
seen in cultures induced with butanoic acid. The short-chain fatty acid pentanoic acid was able
to improve productivity compared to the fed-batch control, but to a lower level than butanoic
acid. The antioxidant, n-acetyl cysteine, was the only molecule evaluated in the test to show a
marked improvement in cell densities over the testing gradient.
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Chapter
IMPROVED GROWTH AND RECOMBINANT PROTEIN PRODUCTIVITY IN CHO
CELLS USING THE COMBINED EFFECTS OF SHORT CHAINFATTY ACIDS WITH
THE ANTIOXIDANT N-ACETYLE CYSTEINE

4.1

Introduction
Within biopharmaceuticals, monoclonal antibodies are an important segment. Seven of

the top ten selling biopharmaceuticals in 2011 were monoclonal antibodies or fragments of
monoclonal antibodies. Monoclonal antibodies are natural occurring glycosylated proteins that
play a major role the body’s immune system. They are monospecific to an epitope target and are
produced by B lymphocytes, a class of immune cells, in response to an antigen. Specific B
lymphocytes only produce one specific antibody. One method for producing the B cell needed
for the fusion is to expose a mouse to an antigen in two phases, a priming dose and a booster
dose. Following treatment with the antigen a sample of the spleen can be harvested. In 1975,
George Kohler and Cesar Milstein demonstrated that a specific B cells could be isolated and
fused with a cancerous myeloma cell line. The B cell bringing the ability to produce a specific
antibody and the myeloma cell conferring the ability to replicate rapidly and indefinitely. This
process, known as hybridoma technology, ushered in a process to allow expanded production of
a monoclonal antibody to a specific target molecule. Following fusion with the myeloma cell
line the hybridoma population can be screened for a population producing the antibody of
interest.
Most therapeutics monoclonal antibodies are either humanized or are human
immunoglobulins (IgG) and are produced as recombinant glycoproteins in mammalian cells
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(Beck et al. 2008). Despite their rapid growth in use, they are generally expensive therapies that
can cost over $100,000 per year or over the course of full treatment (Bioplan Associates 2013).
The high cost of MAb treatment can be attributed to low potency and short half-life, requiring
large dosages and frequent dosages. These factors lead to large amounts of MAb being needed
to treat patient populations. It is estimated that around 90% of the world-wide production
capacity for mammalian cell culture is for MAb production (Bioplan Associates 2013). Much of
this production requires the use of large volume bioreactors at the 10,000 L scale. During
process development and scale-up one of the primary engineering objectives is to optimized the
production process to minimize manufacturing costs.
In an effort to target optimization of recombinant protein production of IgG in CHO cell
lines we sought to analyze the growth and recombinant protein production response to the novel
combination of pentanoic acid induction of protein production and the combined treatment with
the anti-oxidant n-Acetyl Cysteine to minimize detrimental response by the cultured cells to
treatment with the carboxylic acids.
4.2

Materials and Methods
A Chinese Hamster Ovary cell line producing a monoclonal antibody (IgG) was used for

these studies. Seed stocks of the previously suspension adapted cell line were brought out of
cryopreservation and were cultured with CDM4CHO® (HyClone, Thermo Fisher Scientific,
Waltham, Massachusetts). This cell stock was cultured in volume of 100 mL in 250 mL
disposable Erlenmeyer shake flasks in a 37°C, 5%CO 2 incubator, passaged every 3 to 4 days.
Cultures were agitated on a shaker platform at 135 RPM with loosened caps to maintain
adequate gas exchange.
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4.2.1

Cell Line and Media
A Chinese Hamster Ovary cell line producing a monoclonal antibody (IgG) was used for

these studies. The cell line was cultured with CDM4CHO® (HyClone, Thermo Fisher Scientific,
Waltham, Massachusetts). Cell stocks were maintained in 200 mL shake flask cultures in a
37°C, 5%CO2 incubator, passaged every 3 to 4 days.
4.2.2

Component Preparation
Butanoic Acid and pentanoic acid were prepared at a concentration of 250mM in

deionized water. N-Acetyl –cysteine was prepared at a concentration of 500mM in deionized
water.
4.2.3

Bioprocess Experiments
A time course, repeated measure study of the two short chain fatty acids, pentanoic acid

and butanoic acid, were studied independently with n-acetyl cysteine in 5 x 5 factorial designs.
Pentanoic acid and butanoic acid were run from 0 – 5 mM in a two-fold serial dilution gradients
and n-acetyl cysteine was run from 0 – 10 mM in two-fold serial dilution gradients. The samples
were randomized and run in triplicate. Conditions were 1.0 mL cultures run in deep-well 96 well
microtiter plates (Nunc, Thermo Fisher Scientific, Waltham, Massachusetts).
Experimental conditions were cultured in a basal formulation of CDM4CHO®
supplemented with 6 g/L Cell Boost 2® (HyClone, Thermo Fisher Scientific, Waltham,
Massachusetts) process supplement. Cultures were maintained in a 37C, 5%CO2 incubator
active humidification at a relative humidity of 80%. Mixing was provided by orbital shaking at
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1,000 RPM with a 3mm orbit. Culture sterility was maintained using rayon fabric covers to seal
the plates.
All culture conditions were inoculated at 250,000 cells/mL on day 0 and were induced
with butanoic acid or pentanoic acid on day 4. Supplementation of culture with NAC was done
at the time of small molecule induction. Cultures were sampled on days 0, 3, 5, 7, and 10 for cell
quantitation and product titer.
4.2.4

Cell Quantitation
Cell density and viability were determined using. Trypan blue, a dead-cell dye, excluded

by viable cells was used to distinguish the two different cell populations. A high throughput
image cytometer, Cellavista ® Cell Imager (SynenTec, Elmshorn, Germany), was used to count
microtiter plate samples of culture conditions. Aliquots for cell counting were counted
immediately after sampling.
4.2.5

Product Titer Analysis by Biolayer Interpherometry
Samples of 40uL from culture conditions were diluted in phosphate buffered saline (PBS)

in standard 96 well SBS microtiter plates and were kept frozen at -20°C until analysis. Product
titer was determined using a biolayer interpherometry assay with Protein A biosensors using an
Octet QK384 (Fortebio, Menlo Park, CA). A reference standard was generated using a human
IgG (Sigma Aldrich, St. Louis, MO) in the range of 3.16 to 1000 ug/mL.
4.3
4.3.1

Results and Discussion
Effects of Butanoic and Pentanoic Acids in combination with N-Acetyl Cysteine on
Cell Growth Profiles Density
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The treatment of a CHO cell line producing a recombinant IgG with small molecule
enhancers and the anti-oxidant n-acetyl cysteine was analyzed in a scale-down model using
deep-well microtiter plates. The cultures demonstrated expected growth response (Figure14) to
treatments. Significant loss in viable cells was observed in cultures treated with higher
concentrations of small molecule enhancers. Loss of viable cells was observed in cultures treated
with higher concentrations of small molecule enhancers. Higher peak growth was observed in
cultures treated with pentanoic acid relative to cultures treated with butanoic acid (Figure 16).

Figure 14 Response Surface growth promotion study. (A) Butanoic acid and n-acetyl
cysteine. (B) Pentanoic acid and n-Acetyl Cysteine.

Butanoic acid induction in combination with NAC, in a high throughput response surface
methodology design, at a concentration of 0.625 mM butanoic acid and 1.25 mM n-acetyl
cysteine, had a 6.2% increase in growth (Figure14A) compared to the untreated control. At the
same concentration of butanoic acid, but no NAC supplementation the growth was decreased by
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34.6% compared to the non-treated control compared to the 1.25mM NAC treated cultures at the
same butanoic acid concentration.
Pentanoic acid induction in combination with NAC, at a concentration of 0.625 mM
pentanoic acid and 1.25 mM n-acetyl cysteine, had a 16.6% increase in growth (Figure14B)
compared to the untreated control. At the same concentration of pentanoic acid, but no NAC
supplementation the growth was increased by 16.6% compared to the non-treated control and
compared to the 1.25mM NAC treated cultures at the same pentanoic acid concentration.
Higher peak growth was observed in cultures treated with pentanoic acid relative to
cultures treated with butanoic acid. Interestingly, there was improvement in growth of CHO
cultures treated with pentanoic acid relative to the untreated control sample, but this wasn’t
observed in butanoic acid treated samples (Figure 15).

Figure 15 Plot of growth performance of CHO cells with combined Pentanoic Acid (PA)
and n-Acetyl Cysteine treatment (NAC) compared to untreated control.
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4.3.2

Effects of Butanoic and Pentanoic Acids in combination with N-Acetyl Cysteine on
Volumetric Productivity
Comparison of the treatment of cultures with various levels of pentanoic acid and

butanoic acid with the addition of anti-oxidant didn’t show major differences in volumetric
productivity (Figure 16), but did show variation in concentration for peak productivity. Peak
productivity was observed for butanoic acid and NAC at 0.625 mM and 1.25 mM, respectively.
Peak productivity was observed for pentanoic acid and NAC at 1.25 mM and 1.25 mM,
respectively.

Figure
16 Response Surface of production of IgG. (A) Butanoic acid and n-acetyl cysteine. (B)
Pentanoic acid and n-Acetyl Cysteine.

Butanoic acid induction in combination with NAC, in a high throughput response surface
methodology design, at a concentration of 0.625 mM butanoic acid and 1.25 mM n-acetyl
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cysteine, a 3.52 factor increase in production of IgG (Figure 17) compared to the untreated
control. At the same concentration of butanoic acid, but no NAC supplementation produced
87.3% less IgG compared to the 1.25mM NAC treated cultures at the same butanoic acid
concentration.
Pentanoic acid induction in combination with NAC, in a high throughput response
surface methodology design, at a concentration of 1.25 mM pentanoic acid and 1.25 mM nacetyl cysteine, a 3.68 factor increase in production of IgG (Figure 18) compared to the untreated
control. At the same concentration of pentanoic acid, but no NAC supplementation produced
55.7% less IgG compared to the 1.25mM NAC treated cultures at the same pentanoic acid
concentration.
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Figure17 Butanoic Acid and n-Acetyl Cysteine treatment.
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Figure18 Pentanoic Acid and n-Acetyl Cysteine treatment.
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Conclusion
Using the antioxidant n-acetyl cysteine we have shown improved production of IgG in a
CHO cell line cultured with pentanoic acid used as an enhancer of protein production. The
improvement in productivity with the combined treatment of pentanoic acid and n-acetyl
cysteine correlated with improved viability. Co-supplementation of the two molecules may be
an effective tool for use in optimization of cell culture bioprocesses. Butanoic acid and
pentanoic acid can induce increased production of recombinant IgG in CHO cells.
Supplementation of n-acetyl cysteine to pentanoic acid induced cultures can further increase IgG
production increases.
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Chapter
DECREASED APOPTOTIC EFFECT USING THE ANTIOXIDANT N-ACETYLE
CYSTEINE IN COMBINATION WITH TREATMENT OF CHO CELLS WITH THE
SHORT CHAIN FATTY ACIDS BUTANOIC ACID AND PENTANOIC ACID

5.1

Introduction
Tissue plasminogen activator (tPA) is a 68 kDa monomeric serine protease (EC

3.4.21.68) produced primarily by endothelial cells. In blood, it is one of two major activators of
plasminogen, the precursor of plasmin which is a serine protease that can dissolve fibrin blood
clots. A recombinant form of the protein is produced as a biopharmaceutical drug, Activase®,
for treatment of acute myocardial infarction, acute ischemic stroke, pulmonary thrombosis, and
other blood clot conditions (Wagstaff et al. 1995). It is a recombinantly produced protein and is
made in CHO cells and acts as a model for non-IgG biopharmaceutical recombinant protein
production systems.
5.2
5.2.1

Materials and Methods
Cell Line and Media
A Chinese Hamster Ovary cell line, CHO 1-15 500 (ATCC® CRL-9606), producing

human tissue Plasminogen Activator (tPA) was used for these studies. The cell line was cultured
with CDM4CHO® (HyClone, Thermo Fisher Scientific, Waltham, Massachusetts). Cell stocks
were maintained in 200 mL shake flask cultures in a 37°C, 5%CO 2 incubator, passaged every 3
to 4 days.
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Experimental conditions were cultured in CDM4CHO® supplemented with 2 g/L Cell
Boost 2® (HyClone, Thermo Fisher Scientific, Waltham, Massachusetts) process supplement.
5.2.2

Component Preparation
Butanoic Acid was prepared at a concentration of 250mM in deionized water. Pentanoic

acid was prepared at a concentration of 250mM in deionized water. N-Acetyl Cysteine was
prepared at a concentration of 500mM.
5.2.3

Bioprocess Experiments
Disposable shake flasks were used for 50 mL scale-down culture testing of butanoic acid

and pentanoic acid with n-Acetyl Cysteine supplementation for studying apoptosis and
productivity.
Disposable 125 mL Erlenmeyer shake flasks were used for 50 mL scale-down culture
testing of butanoic acid and pentanoic acid with n-acetyl cysteine supplementation for studying
apoptosis and productivity. Cultures were maintained in a non-humidified 37C, 5%CO2
incubator. Mixing was provided by an orbital shaker, shaken at 135 RPM with a 19 mm orbit.
All culture conditions were inoculated at 250,000 cells/mL on day 0 and were induced
with butanoic acid or pentanoic acid on day 3. Supplementation of culture with NAC was done
at the time of small molecule induction of cultures. Cultures were sampled on days 0, 3, 4, 5, 6,
7, and 10 for cell quantitation and product titer. Apoptosis was analyzed on day 6, three days
post induction with butanoic acid and pentanoic acid.
5.2.4

Cell Quantitation
Cell density and viability were determined using Trypan Blue dye exclusion assays.

Microtiter plate cultures were counted using on a Cellavista® Cell Imager (SynenTec, Elmshorn,
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Germany). Shaker flask cultures were counted using an automated ViCell® XR Cell Viability
Analyzer (Beckman Coulter, Fullerton, California). Aliquots for cell counting were counted
immediately after sampling.
5.2.5

Apoptosis Analysis by Flow Cytometry
Apoptosis, genetically programmed cell death, is a natural response for removal of

unwanted cells (Elmore 2007). The process of programmed cell death is characterized by
multiple cellular events; chromatin condensation, cell volume loss, DNA fragmentation, and the
loss of phospholipid membrane integrity. The loss of phospholipid membrane integrity results in
phosphatidylserine (Bratton et al. 1997) exposure on the extracellular cell membrane.
Phosphatidylserine, a negatively charged phospholipid component of the inner cell membrane,
when exposed on the outer cell membrane signals recognition of the of the apoptotic cells
initiating a non-inflammatory phagocytic response.
Annexins are a family of proteins that bind to cell membranes. Annexin V binds with
high specificity to phosphatidylserine. The binding takes place rapidly with high affinity and is
dependent on calcium for binding.
Apoptosis was analyzed following treatment of cells with butanoic acid or pentanoic acid
combined with treatment by n-Acetyl Cysteine. Early apoptosis was monitored by
phosphatidylserine exposure on the cell surface using an fluorescein isothiocyanate labeled
Annexin V (Vermes et al. 1995). To distinguish dead cells from apoptotic cells propidium
iodide was used to label dead cells. Propidium iodide is a fluorescent molecule that intercalates
in dead cell and binds with nucleic acids. Annexin V, propidium iodide treated cells were
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analyzed using a BD Accuri™ C6 Flow Cytometer (BD Biosciences, San Jose, CA) with a
HyperCyt® Autosampler (Intellicyt Corporation, Albuquerque, NM).
5.2.6

Product Titer Analysis by Enzyme-Linked Immunosorbent Assay
Product titer was determined using a sandwich enzyme-linked immunosorbent assay

(ELISA). An affinity purified sheep anti-tPA IgG was used as a capture antibody by coating a
standard ELISA 96 well plate. A reference standard curve was generated using a concentrated
and titered recombinant tPA control in the range of 3.16 to 1000 ug/mL. Samples from culture
conditions which had previously been stored frozen at -20°C were thawed and dilutions were
prepared in phosphate buffered saline (PBS) at a dilution factor of 1:2000. Sample were then
applied to the capture antibody prepared plates. A sheep anti-tPA conjugated to horse-radish
peroxidase was used as the detecting antibody. A stable liquid one-step 3,3′,5,5′tetramethylbenzidine (TMB) liquid was used as a substrate for colorimetric analysis. A
SpectraMax M2 (Molecular Devices, Sunnyvale, CA) was used to analyze the assay plates at a
detection wavelength of 450 nm.
5.3

Results and Discussion
The addition of the anti-oxidant n-Acetyl Cysteine to the culture of CHO cells producing

a recombinant protein ameliorated the apoptotic effect of carboxylic acid treatment with butanoic
acid and pentanoic acid.
5.3.1

Effects of Butanoic Acid and Pentanoic Acid in combination with N-Acetyl Cysteine on
Apoptosis
The treatment of CHO IgG cell line producing a recombinant IgG1 was cultured in small

volume shake flasks.

Cultures were treated with different levels of butanoic acid, pentanoic
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acid, and the anti-oxidant n-acetyl cysteine (NAC) on day 3. On day 7 samples were analyzed
for apoptosis using Annexin V and propidium iodide with analysis by flow cytometry. Annexin
V was used identify cells that were entering early apoptosis and propidium iodide was used to
identify cells that had died. The control culture had a viability of 86.9% (Table 6) and showed
normal growth characteristics.

Butanoic Acid

Pentanoic Acid

n-Acetyl Cysteine

Control

No SME

Figure 19 Flow cytometry analysis of carboxylic acid treatment with the antioxidant nAcetyl Cysteine compared to an untreated control.
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Table 6 Viability of combined carboxylic acid and antioxidant treatment.

Table 7 Early Apoptosis results of combined carboxylic acid and antioxidant treatment.

The culture treated with n-acetyl cysteine only showed minimal improvements in culture
viability and cells not entering early apoptosis (Table 6), 1.4% and 1.3%, respectively.
Treatment of cultures with sodium butyrate and NAC showed minimal improvement in viability
but improved the percentage of cells entering early apoptosis by 5.3% (Table 6). Pentanoic acid
and NAC treated culture demonstrated 6.4% improvement in viability and 10.0% improvement
in preventing cells from entering early apoptosis (Table 7). All conditions showed improved
productivity relative to the untreated control (Table 8). In this study butanoic demonstrated a
5.7% loss in productivity when treated with NAC, however, pentanoic acid treatment with NAC
demonstrated an improvement in productivity of 19.5% (Figure 8).
5.3.2

Comparison of Viability, Early-Apoptosis and Productivity Improvement
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Treatment of pentanoic acid containing culture with n-acetyl cysteine demonstrated a
19.5% increase in productivity and a 7.3% increase in viability (Table 8). A reduction of 5.72%
in the amount of IgG produced was observed in butanoic acid cultures treated with the
antioxidant n-acetyl cysteine. Reduced levels of apoptosis were observed in cultures of both
pentanoic acid and butanoic acid.
Table 8 Productivity results of combined carboxylic acid and antioxidant treatment.

5.4

Discussion
Butanoic acid is a well-known small molecule enhancer of protein production, but

induces apoptosis in many different cell types. n-Acetyl Cysteine is a thiol containing antioxidant that has been shown to reduce apoptosis induction by butanoic acid. Pentanoic acid has
been shown to have similar properties for inducing higher production levels of proteins. We
have been able to demonstrate that pentanoic acid can improve protein production. It also
shows increased apoptosis, which can be delayed by treatment with n-acetyl cysteine.
Here it was shown that pentanoic acid can improve the volumetric production of IgG in
CHO cells treated during log phase growth. This stimulation was positive but didn’t achieve the
productivity levels achieve with butanoic acid supplementation. Pentanoic acid experiments
showed similar improvements in productivity to those observe by Liu et al. (Liu et al. 2001c).
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We were able to show apoptosis markers in conditions treated with both pentanoic acid
and butanoic acid. Although the supplementation of the anti-oxidant n-Acetyl Cysteine into both
treatments showed improvements in cell health, only pentanoic acid showed improvement
productivity. We did observe further performance increases to those previously observed by
others for increased productivity with the addition of anti-oxidants (Oh et al. 2005). However,
the overall volumetric productivity was 1.7-fold higher in butanoic acid treated cultures.
5.5

Conclusion
As seen in previous studies, pentanoic acid wasn’t able to stimulate higher productivity

than butanoic acid. However, the combined treatment with the antioxidant n-acetyl cysteine was
able to improve productivity in pentanoic acid treated cultures to a greater degree, than butanoic
acid treated conditions. Apoptosis reduction by treatment with n-acetyl cysteine in cultures
induced with carboxylic acid was shown to be a viable method to improve productivity.
5.6
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Chapter
SUMMARY, CONCLUSIONS, AND RECOMMONDENDATIONS
6.1

Summary and Conclusions
In an effort to optimize the bioprocess manufacturing of recombinant proteins by

increasing the volumetric titer, the combination for protein induction of the short chain fatty acid
pentanoic acid and the antioxidant n-acetyl cysteine is a viable method for process evaluation.
The improvement in productivity with the combined treatment correlated with improved viability
and a reduction in cells entering apoptosis. Butanoic acid and pentanoic acid were both shown to
induce increased production of recombinant IgG in CHO cells. The levels of improved protein
production were shown to be cell line dependent for both of these carboxylic acids.
6.2

Recommendations
A. Perform scale-up testing of scale-down testing from research. In these studies, scaledown models of larger bioprocess systems were used. Benchtop bioreactors allow the
testing of the samples under more controlled conditions, specifically of control dissolved
oxygen (DO) and pH conditions. These factors being held at a steady state level allow
optimization to add in specific parameter controls at targeted levels.
B. Study in chemostat culture would allow for steady analysis looking at changes in oxygen
consumption, glucose consumption, lactic acid production, protein production, death rate
and growth rate under various steady-state conditions.
C. Investigate effect of genetic modification of the cell line, by such things as bcl-2
overexpression with addition of various small molecule enhancers of production.
D. Test mechanism of action of PA and other SME for HDAC activity.
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E. New clones are invariably different, so design and development of standardized screening
process can allow rapid identification of optimization pathways. Other cell lines such as
CHO1-15, non-IgG producers
F. SME. Perform broad screening assays of small molecule enhancers of protein
productivity. This can be achieved by development of high throughput screening assays
under appropriate culture conditions. Molecule that could be screened are short-chain
fatty acids (SCFA), including butanoic acid and pentanoic acid, aromatic carboxylic
acids, hydroxamic acids, acetamides, DMSO, rapamycin, etc. Screening can narrow
down the scope of analysis allowing best performers to proceed to additional testing.
G. Antioxidants. Develop a high throughput screening assay of a broad spectrum of
antioxidants. Look at antioxidants such as what are the classes of antioxidants.
H. Combined effect of antioxidants and SME’s. Look at different screening designs to
determine if their combinations of SME may act synergistically to improve productivity.
I. Analyze small molecule enhancers effect on cell cycle. Is there a particular supplement
that will improve the cell survival of samples in the G0 cell cycle?
J. Look at critical quality attributes. Study the glycosylation pattern of SME treated and
AOx treated. Glycosylation deamidation. Protein aggregates. Bioactivity. Look at Sialic
acid content of antibodies. Maybe Lectin binding. Look at protein aggregation, sequence
truncation, and charge variants. Determine if there is a time-coarse variation in change of
critical quality attributes. (Sung and Lee 2005) Final product activity assay.
K. Focus comparison of feeding strategies effect on induction. Low temperature shift
combined affect. Analyze effect of SME addition rate of apoptosis. Rather than a bolus
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induction, could a slow addition improve effect while minimizing negative effects like
apoptosis.
L. Analyze intracellular igg versus expression for potential that over production may be
cause lower levels Analysis of transcription and translation mRNA levels
6.3
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APPENDIX

APPENDIX A STUDY DESIGN/SAMPLING
7.1

Apoptosis Analysis - Annexin V/Propidium Iodide
Apoptosis is a process of programmed cell death, initiated by stimulation of signaling

cascade. The monitoring of apoptosis offers a tool in biological discovery process. One method
for monitoring apoptosis is the use Annexin V, that can be bound to a fluorescent molecule such
as fluorescein isothiocyanate (FITC). This molecule can selectively bind to the cell surface
protein phosphatidyl-serine. Phosphatidyl-serine is typically attached to the interior of cell
membrane. During apoptosis, prior to the loss of cell membrane integrity, phosphatidyl-serine
will shift to the extracellular side of the cell membrane. This process acts as a marker for early
apoptosis. Staining with Annexin V is generally combined with a vital dye such as propidium
iodide (PI) or with 7-Amino-Acintomycin (7-AAD). PI and 7-AAD are able to stain dead and
damaged cells because their membrane is permeable. Cells not staining Annexin V and not for
PI are considered viable and non-apoptotic, those staining for Annexin V but not PI are
considered to be early apoptotic, and those staining for both dyes are considered in late apoptosis
or dead. Using a combination of these dyes is not able to distinguish between cells that have
died from apoptosis or necrosis. However, measuring the cell population over time, one can see
the progression of the cell population from viable, living cells to early apoptotic cells, to late
stage apoptosis and death.
7.2

Staining Protocol

Wash cells twice with cold PBS and then resuspend cells in 1X Binding Buffer at a concentration
of 1 x 10^6 cells/ml.
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Transfer 100 μL of the solution (1 x 10^5 cells) to a 5 ml culture tube.
Add 5 μL of FITC Annexin V and 5 μL PI.
Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark.
Add 400 μL of 1X Binding Buffer to each tube. Analyze by flow cytometry within 1 hr.
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APPENDIX B SUPPLEMENTARY DATA
Experiment 1
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Experiment 2
BA and NAC Protein Production
One-way Analysis of Variance (ANOVA)
BA ICA

BA P

BA qp
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Experiment 2
PA and NAC Protein Production
One-way Analysis of Variance (ANOVA)
PA ICA

PA P

PA qp

